| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6409990 | CARDINAL HEALTH 414 | Macromolecular carrier for drug and diagnostic agent delivery |
May, 2025
(1 year, 7 months from now) | |
| US9439985 | CARDINAL HEALTH 414 | Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran |
Jan, 2029
(5 years from now) | |
Lymphoseek Kit is owned by Cardinal Health 414.
Lymphoseek Kit contains Technetium Tc-99M Tilmanocept.
Lymphoseek Kit has a total of 2 drug patents out of which 0 drug patents have expired.
Lymphoseek Kit was authorised for market use on 13 March, 2013.
Lymphoseek Kit is available in injectable;injection dosage forms.
The generics of Lymphoseek Kit are possible to be released after 30 January, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | May 19, 2024 |
Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient
Market Authorisation Date: 13 March, 2013
Treatment: NA
Dosage: INJECTABLE;INJECTION
LYMPHOSEEK KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic